Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 150,000 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. This trade represents a 90.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock traded up $0.30 on Friday, hitting $23.80. 1,371,532 shares of the company's stock traded hands, compared to its average volume of 468,320. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29. The company's fifty day simple moving average is $22.20 and its 200 day simple moving average is $20.51. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -9.15 and a beta of -0.04.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, sell-side analysts anticipate that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have recently commented on NAMS. HC Wainwright reissued a "buy" rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC decreased their price target on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Scotiabank increased their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $43.80.

Hedge Funds Weigh In On NewAmsterdam Pharma

Institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC grew its holdings in NewAmsterdam Pharma by 35.6% in the 3rd quarter. FMR LLC now owns 330,412 shares of the company's stock worth $5,485,000 after acquiring an additional 86,712 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in NewAmsterdam Pharma by 1,231.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company's stock worth $3,972,000 after acquiring an additional 221,305 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after acquiring an additional 14,280 shares during the last quarter. State Street Corp grew its holdings in NewAmsterdam Pharma by 168.7% in the 3rd quarter. State Street Corp now owns 37,915 shares of the company's stock worth $629,000 after acquiring an additional 23,805 shares during the last quarter. Finally, abrdn plc boosted its stake in shares of NewAmsterdam Pharma by 69.8% during the 3rd quarter. abrdn plc now owns 129,060 shares of the company's stock valued at $2,142,000 after purchasing an additional 53,060 shares in the last quarter. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.